The article recommends three discounted growth stocks with potential to double: Oracle, trading at a 60% discount from its 52-week high with a strong $523 billion backlog despite debt concerns; Figma, down 80% from its post-IPO high but showing strong product adoption with 136% net dollar retention; and Zscaler, down 55% since November but maintaining robust 26% revenue growth and approaching profitability.

Software stocks have plunged 24% year-to-date amid AI disruption fears, but some SaaS stocks appear oversold. Figma, down 74% from its peak, shows strong growth with 40% revenue increase and GAAP profitability, plus aggressive AI product development. Axon Enterprise, a law enforcement technology leader, posted 39% revenue growth and is investing heavily in AI tools like Draft One for police reports, forecasting $8 billion revenue by 2028.

Figma stock has recovered after earnings, showing 41% revenue growth and positive free cash flow in 2025, but remains down 80% from its IPO high. While the company has carved a niche in UI design where Adobe has struggled, it still operates at a loss with elevated valuation multiples. The stock is recommended only for risk-tolerant investors willing to add shares gradually.

General Magic, a Toronto-based AI company, announced a $7.2M seed funding round led by Radical Ventures to expand its SMS-based AI agents that automate insurance workflows. The platform reduces inbound calls by 30%, deploys in 3 minutes, and saves teams 250+ hours monthly by handling pre-quote, post-quote, and claims coordination. Early deployments with major insurers have reduced time-to-quote from 30 minutes to under 3 minutes.

Cathie Wood's Ark Invest added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday as all three growth stocks trade significantly below their 2025 highs. Figma showed strong Q4 results with 40% revenue growth and improved margins, while CoreWeave benefits from AI infrastructure demand. Recursion faces headwinds after Nvidia exited its stake, though the company remains a clinical-stage AI-driven biotech play.

Ten large-cap stocks were top performers last week, with First Majestic Silver leading gains at 25.23% following better-than-expected Q4 results. Other notable gainers include Moderna (19.68%) on FDA seasonal flu vaccine review news, Global Payments (19.52%) with strong Q4 earnings and a $2.6B buyback authorization, and Coinbase (11.32%). Companies like Omnicom, Garmin, Figma, and Pan American Silver also reported strong quarterly results and positive guidance.

Figma stock surged 18.39% in extended trading after beating Q4 earnings expectations. The company reported EPS of $0.08 versus $0.07 estimate and revenue of $303.78 million versus $293.15 million estimate. Figma also provided strong 2026 guidance, projecting Q1 revenue of $315-317 million and full-year revenue of $1.37-1.374 billion, both exceeding analyst expectations. The company highlighted strong growth in Figma Make with 70%+ quarter-over-quarter user growth and new AI features.

a16z Capital Management disclosed a $465 million investment in Navan, acquiring approximately 27.2 million shares in Q4 2025. The investment makes Navan the fund's second-largest holding at 29.4% of its 13F reportable assets. Navan has evolved from a corporate travel booking platform into an integrated enterprise spending and payments solution leveraging AI for travel, expense, and payment management.

Figma stock surged 9% following a broader software sector rebound after JPMorgan Chase and Goldman Sachs pushed back against the software sell-off, calling it overdone. The stock has plunged over 85% from its high due to AI disruption concerns, but investors see it as a buying opportunity. Figma will report Q4 earnings on Feb. 18, which could significantly move the stock.

Figma stock has declined over 25% from its IPO price despite strong 41% revenue growth. While the company faces significant operating losses and high valuation concerns, its massive $33 billion addressable market, strong free cash flow generation, and revenue growth far exceeding market averages suggest potential for long-term gains over the next five years.

Figma stock has plummeted 83% from its IPO high of $142.92 to around $22.51 in six months, driven by AI concerns about reduced demand for design software. However, the company maintains solid 38% year-over-year revenue growth and 35% guidance for Q4, with recent profitability. The analyst suggests the sell-off may be an overreaction and the stock could be an underrated bargain buy.

Figma's stock has plummeted 80.51% from its all-time high of $143.45 to $22.51 following the expiration of its 180-day post-IPO lock-up period on January 27, 2026. Early employees who waited a decade for the IPO now face significant losses as the stock trades well below its $33 IPO price. The collapse stems from analyst downgrades, sector volatility, and investor concerns about the company's competitive position against AI-integrated rivals like Adobe and Microsoft.